DNA polymerase mutant for sequencing
By transforming the active site of Pyrococcus abyssi DNA polymerase, mutants were obtained, which solved the problems of the polymerization speed and quality of existing sequencing enzymes, improved the incorporation efficiency of non-natural dNTP, and improved the sequencing speed and quality. More efficient nucleic acid amplification and sequencing performance are achieved.
Patent Information
- Application Number
- PCT/CN2023/098118
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Filing Date
- 2023-06-02
- Publication Date
- 2024-12-05
AI Technical Summary
Existing sequencing enzymes have problems in polymerization speed and sequencing quality, especially the polymerization ability of artificially modified nucleotides or nucleotide analogs is low, which affects the sequencing signal and quality.
By engineering the enzyme of thermostable B family polymerases of thermophilic archaea, especially the active sites of Pyrococcus abyssi DNA polymerase, mutants are obtained to improve their incorporation efficiency of specific non-natural dNTPs, thereby improving the Sequencing speed and quality of synthesis and sequencing method.
The efficient addition of specific non-natural dNTPs is achieved, which improves the sequencing speed and quality, and provides more efficient nucleic acid amplification and sequencing performance.
Smart Images

Figure PCTCN2023098118-FTAPPB-I100001 
Figure PCTCN2023098118-FTAPPB-I100002 
Figure PCTCN2023098118-FTAPPB-I100003
Abstract
Description
DNA polymerase mutants for sequencing Technical Field
[0001] The present invention relates to the field of biotechnology, and more specifically, to a DNA polymerase mutant for sequencing, and in particular to a DNA polymerase mutant, a nucleic acid molecule, an expression vector, a recombinant cell, a recombinant strain, a method for DNA polymerase mutant, a complex, a method for nucleic acid sequencing, a nucleic acid sequencing kit, and uses thereof, and uses thereof in preparing products related to catalyzing DNA amplification or nucleic acid sequencing. Background Art
[0002] Nucleic acid sequences are crucial for understanding gene function and are widely used in genetic analysis, and DNA sequencing methods are important tools in genetic analysis. The second-generation high-throughput DNA sequencing method based on sequencing by synthesis (SBS) is currently the most widely used sequencing technology. Compared with first-generation sequencing, it has the following advantages: fast sequencing speed and high throughput, which can complete large-scale genome sequencing in a short period of time; low sequencing cost, with the sequencing price per base much lower than first-generation sequencing; high sequencing accuracy, which can detect low-frequency variants and heterozygous sites; high sequencing flexibility, which can be applied to different target regions and sample types. Second-generation sequencing has a wide range of applications in the biomedical field, such as transcriptome sequencing, epigenetic sequencing, whole-genome association analysis, drug resistance detection and other applications (such as genetic identification, forensic analysis, genetic counseling, medical diagnosis).
[0003] As one of the most important components in second-generation sequencing, sequencing polymerase plays an important role in the sequencing process. The principle of second-generation sequencing is sequencing by synthesis, that is, the sequence of DNA is determined by capturing the special labels carried by the newly added bases (generally fluorescent molecular labels) during the DNA replication process. Sequencing polymerase is responsible for pairing and connecting the labeled bases with the template chain to form a complementary DNA chain. In this sequencing method, the addition and detection of artificially modified nucleotides or nucleotide analogs (for example, DNA polymerase with fluorescently labeled reversible terminators) is crucial. In DNA polymerization, the biggest limiting factor is the low polymerization ability of existing natural polymerases for artificially modified nucleotides or nucleotide analogs. In view of this, enhancing the polymerization ability of polymerases for artificially modified nucleotides or nucleotide analogs is a key step in this type of sequencing method.
[0004] Based on the amino acid sequence differences between Escherichia coli polymerases I, II, and III, DNA polymerases are divided into three families, designated A, B, and C. While the nucleotide binding sites of A and B polymerases are structurally similar, the motifs of the polymerases from different families differ significantly, correspondingly representing the recognition mechanisms of nucleotides and their analogs. Among them, the thermostable B family polymerases from thermophilic archaea have the best incorporation performance for various nucleotide analogs, and their mutants are widely used in various next-generation sequencing methods. The thermostable B family polymerases of thermophilic archaea include KOD (Thermococcus kodakaraensis), 9°N (Thermococcus sp.9°N), TGO (Thermococcus gorgonarius), TOK (Desulfurococcus sp.Tok), Vent DNA polymerase (Thermococcus litoralis), JDF-3 and pfu DNA polymerase (Pyrococcus furiosis). The main amino acid sequences of their DNA polymerase active sites are conserved, but these conserved enzyme active sites are also easy to change, allowing the addition of non-natural specific dNTP polymerases while maintaining DNA activity.
[0005] Summary of the Invention
[0006] The present invention aims to solve at least one of the technical problems existing in the prior art to at least a certain extent.
[0007] To address the problems of polymerization speed and sequencing quality (e.g., lag (affecting sequencing signal and quality) and strand bias) in existing sequencing enzymes, the inventors have engineered active sites in thermostable B-family polymerases from thermophilic archaea to obtain novel DNA polymerase mutants. These mutants significantly improve the polymerase's incorporation efficiency for specific non-natural dNTPs, thereby enhancing the sequencing speed and quality of sequencing by synthesis (SBS).
[0008] To this end, in one aspect, the present invention provides a DNA polymerase mutant. According to an embodiment of the present invention, the mutant comprises: compared to a Pyrococcus abyssi DNA polymerase exo- (removing 3'–5' exonuclease proofreading activity) mutant, at least three amino acid mutations at the following four sites or functionally equivalent sites: positions 409, 410, 411, and 486; the Pyrococcus abyssi DNA polymerase Exo- mutant has the amino acid sequence shown in SEQ ID NO: 1. The DNA polymerase mutant described in the embodiment of the present invention can effectively improve the polymerase's incorporation efficiency of specific non-natural dNTPs, thereby having important significance in improving the sequencing speed and sequencing quality of the SBS sequencing method.
[0009] It should be noted that the amino acid positions in the amino acid sequence of the DNA polymerase mutant described in the present application are located with reference to the amino acid positions in the amino acid sequence of the wild-type Pyrococcus abyssi DNA polymerase or the wild-type Pyrococcus abyssi DNA polymerase exo-mutant.
[0010] According to an embodiment of the present invention, the above-mentioned DNA enzyme mutant may further include at least one of the following additional technical features:
[0011] According to an embodiment of the present invention, the DNA polymerase mutant has at least 90% identity with the Pyrococcus abyssi DNA polymerase exo-mutant.
[0012] According to an embodiment of the present invention, the mutant has the following mutations:
[0013] (1) The amino acid L at position 409 is mutated to A, V, Y, H, F, or Q;
[0014] (2) amino acid Y at position 410 mutated to A or G;
[0015] (3) amino acid P at position 411 is not mutated or is mutated to V, G, C, or S;
[0016] (4) The amino acid A at position 486 is mutated to I, K, L, M, W, or F.
[0017] According to an embodiment of the present invention, the mutant has any one of the following combined mutations (1)-(2):
[0018] (1) The amino acid Y at position 410 is mutated to A, the amino acid L at position 409 is mutated to A, V, Y, H, F, or Q, the amino acid P at position 411 is mutated to V, G, C, S, or no mutation, and the amino acid A at position 486 is mutated to I, K, L, M, W, or F; or
[0019] (2) The amino acid Y at position 410 mutates to G, the amino acid L at position 409 mutates to A or V or Y or H or F or Q, the amino acid P at position 411 mutates to V or G or C or S or does not mutate, and the amino acid A at position 486 mutates to I or K or L or M or W or F.
[0020] According to an embodiment of the present invention, the mutant has any one of the following combined mutations (1)-(7):
[0021] (1) The amino acid Y at position 410 is mutated to A, the amino acid L at position 409 is mutated to A, the amino acid P at position 411 is mutated to G, C, S, or no mutation, and the amino acid A at position 486 is mutated to I, K, L, M, W, or F; or
[0022] (2) amino acid Y at position 410 is mutated to A, amino acid L at position 409 is mutated to V, amino acid P at position 411 is mutated to V, G, C, or no mutation, and amino acid A at position 486 is mutated to I, L, W, or F; or
[0023] (3) amino acid Y at position 410 mutates to A, amino acid L at position 409 mutates to Y, amino acid P at position 411 mutates to V or G or does not mutate, and amino acid A at position 486 mutates to L; or
[0024] (4) amino acid Y at position 410 mutates to A, amino acid L at position 409 mutates to H, amino acid P at position 411 mutates to V or G or does not mutate, and amino acid A at position 486 mutates to L; or
[0025] (5) The amino acid Y at position 410 is mutated to A, the amino acid L at position 409 is mutated to F, the amino acid P at position 411 is mutated to V or G or is not mutated, and the amino acid A at position 486 is mutated to L; or
[0026] (6) The amino acid Y at position 410 is mutated to A, the amino acid L at position 409 is mutated to Q, the amino acid P at position 411 is mutated to G or not mutated, and the amino acid A at position 486 is mutated to L; or
[0027] (7) The amino acid Y at position 410 mutated to G, the amino acid L at position 409 mutated to V, the amino acid P at position 411 was not mutated, and the amino acid A at position 486 was mutated to I, K, M, or F.
[0028] According to some specific embodiments of the present invention, the sequencing recombinases (obtained from the DNA polymerase mutants of the present invention) produced by different mutation sites have different relative activities, which can provide more options for actual production needs.
[0029] According to an embodiment of the present invention, the mutant has any one of the combined mutations (1)-(36):
[0030] (1) L at position 409 is mutated to A, Y at position 410 is mutated to A, P at position 411 is not mutated, and A at position 486 is mutated to I; or
[0031] (2) L at position 409 is mutated to V, Y at position 410 is mutated to A, P at position 411 is not mutated, and A at position 486 is mutated to L; or
[0032] (3) L at position 409 is mutated to A, Y at position 410 is mutated to A, P at position 411 is not mutated, and A at position 486 is mutated to W; or
[0033] (4) L at position 409 is mutated to V, Y at position 410 is mutated to G, P at position 411 is not mutated, and A at position 486 is mutated to K; or
[0034] (5) L at position 409 is mutated to V, Y at position 410 is mutated to G, P at position 411 is not mutated, and A at position 486 is mutated to I; or
[0035] (6) L at position 409 is mutated to A, Y at position 410 is mutated to A, P at position 411 is not mutated, and A at position 486 is mutated to M; or
[0036] (7) L at position 409 is mutated to V, Y at position 410 is mutated to G, P at position 411 is not mutated, and A at position 486 is mutated to F; or
[0037] (8) L at position 409 mutates to V, Y at position 410 mutates to A, P at position 411 mutates to V, and A at position 486 mutates to L; or
[0038] (9) L at position 409 is mutated to A, Y at position 410 is mutated to A, P at position 411 is not mutated, and A at position 486 is mutated to F; or
[0039] (10) L at position 409 mutates to A, Y at position 410 mutates to A, P at position 411 mutates to G, and A at position 486 mutates to I; or
[0040] (11) L at position 409 mutates to A, Y at position 410 mutates to A, P at position 411 mutates to C, and A at position 486 mutates to I; or
[0041] (12) L at position 409 is mutated to Y, Y at position 410 is mutated to A, P at position 411 is not mutated, and A at position 486 is mutated to L; or
[0042] (13) L at position 409 mutates to A, Y at position 410 mutates to A, P at position 411 mutates to S, and A at position 486 mutates to K; or
[0043] (14) L at position 409 mutates to Y, Y at position 410 mutates to A, P at position 411 mutates to G, and A at position 486 mutates to L; or
[0044] (15) L at position 409 mutates to Y, Y at position 410 mutates to A, P at position 411 mutates to V, and A at position 486 mutates to L; or
[0045] (16) L at position 409 is mutated to H, Y at position 410 is mutated to A, P at position 411 is not mutated, and A at position 486 is mutated to L; or
[0046] (17) L at position 409 is mutated to F, Y at position 410 is mutated to A, P at position 411 is not mutated, and A at position 486 is mutated to L; or
[0047] (18) L at position 409 is mutated to A, Y at position 410 is mutated to A, P at position 411 is not mutated, and A at position 486 is mutated to L; or
[0048] (19) L at position 409 mutates to A, Y at position 410 mutates to A, P at position 411 mutates to C, and A at position 486 mutates to M; or
[0049] (20) L at position 409 is mutated to V, Y at position 410 is mutated to G, P at position 411 is not mutated, and A at position 486 is mutated to M; or
[0050] (21) L at position 409 mutates to A, Y at position 410 mutates to A, P at position 411 mutates to G, and A at position 486 mutates to W; or
[0051] (22) L at position 409 mutates to A, Y at position 410 mutates to A, P at position 411 mutates to G, and A at position 486 mutates to M; or
[0052] (23) L at position 409 is mutated to V, Y at position 410 is mutated to A, P at position 411 is not mutated, and A at position 486 is mutated to W; or
[0053] (24) L at position 409 mutated to V, Y at position 410 mutated to A, P at position 411 mutated to C, and A at position 486 mutated to L; or
[0054] (25) L at position 409 mutates to Q, Y at position 410 mutates to A, P at position 411 mutates to G, and A at position 486 mutates to L; or
[0055] (26) L at position 409 mutates to H, Y at position 410 mutates to A, P at position 411 mutates to G, and A at position 486 mutates to L; or
[0056] (27) L at position 409 mutates to A, Y at position 410 mutates to A, P at position 411 mutates to S, and A at position 486 mutates to F; or
[0057] (28) L at position 409 is mutated to V, Y at position 410 is mutated to A, P at position 411 is not mutated, and A at position 486 is mutated to I; or
[0058] (29) L at position 409 mutates to H, Y at position 410 mutates to A, P at position 411 mutates to V, and A at position 486 mutates to L; or
[0059] (30) L at position 409 mutated to A, Y at position 410 mutated to A, P at position 411 mutated to S, and A at position 486 mutated to I; or
[0060] (31) L at position 409 mutates to A, Y at position 410 mutates to A, P at position 411 mutates to S, and A at position 486 mutates to M; or
[0061] (32) L at position 409 mutates to F, Y at position 410 mutates to A, P at position 411 mutates to G, and A at position 486 mutates to L; or
[0062] (33) L at position 409 mutates to V, Y at position 410 mutates to A, P at position 411 mutates to G, and A at position 486 mutates to L; or
[0063] (34) L at position 409 is mutated to V, Y at position 410 is mutated to A, P at position 411 is not mutated, and A at position 486 is mutated to F; or
[0064] (35) L at position 409 mutates to A, Y at position 410 mutates to A, P at position 411 mutates to G, and A at position 486 mutates to F; or
[0065] (36) L at position 409 mutated to F, Y at position 410 mutated to A, P at position 411 mutated to V, and A at position 486 mutated to L.
[0066] According to an embodiment of the present invention, the mutant has the following mutations:
[0067] (1) L at position 409 is mutated to V, Y at position 410 is mutated to G, P at position 411 is not mutated, and A at position 486 is mutated to I; or
[0068] (2) L at position 409 is mutated to A, Y at position 410 is mutated to A, P at position 411 is not mutated, and A at position 486 is mutated to I; or
[0069] (3) L at position 409 mutates to A, Y at position 410 mutates to A, P at position 411 does not mutate, and A at position 486 mutates to M; or
[0070] (4) L at position 409 is mutated to A, Y at position 410 is mutated to A, P at position 411 is not mutated, and A at position 486 is mutated to L; or
[0071] (5) L at position 409 is mutated to V, Y at position 410 is mutated to A, P at position 411 is not mutated, and A at position 486 is mutated to I; or
[0072] (6) L at position 409 mutated to A, Y at position 410 mutated to A, P at position 411 mutated to C, and A at position 486 mutated to F.
[0073] According to some specific embodiments of the present invention, the sequencing recombinases (obtained from the DNA polymerase mutants of the present invention) produced by different mutation sites have different relative activities, which can provide more options for actual production needs.
[0074] It should be noted that the amino acid sequences of the above mutants were all obtained by mutation based on the sequence of SEQ ID NO: 1.
[0075] According to some specific embodiments of the present invention, when the amino acid sequence of the DNA polymerase mutant has the above-mentioned mutation, the relative activity of the recombinant polymerase obtained compared to the existing mutation is stronger, and it can effectively add non-natural dNTP containing a fluorescently labeled 3'O-reversible terminator to the DNA chain, thereby improving the sequencing speed and sequencing quality.
[0076] It should be noted that the wild-type Pyrococcus abyssi DNA polymerase is unable to incorporate specific non-natural dNTPs (e.g., non-natural dNTPs containing a 3'O-reversible terminator) into the DNA chain. Therefore, the inventors designed a mutant of Pyrococcus abyssi DNA polymerase to add specific non-natural dNTPs into the DNA chain.
[0077] In a second aspect of the present invention, a nucleic acid molecule is provided. According to an embodiment of the present invention, the nucleic acid molecule encodes the DNA polymerase mutant described in the first aspect of the present invention. The DNA polymerase mutant encoded by the nucleic acid molecule can be obtained in large quantities in vivo or in vitro.
[0078] In a third aspect of the present invention, the present invention provides an expression vector. According to an embodiment of the present invention, the expression vector comprises the nucleic acid molecule described in the second aspect of the present invention.
[0079] It should be noted that the expression vector may further include a promoter, and the promoter is operably connected to the nucleic acid molecule.
[0080] According to an embodiment of the present invention, the expression vector is a non-pathogenic viral vector, and the non-pathogenic viral vector includes an adenoviral vector or a retroviral vector.
[0081] In a fourth aspect, the present invention provides a recombinant cell. According to an embodiment of the present invention, the recombinant cell carries the nucleic acid molecule described in the second aspect of the present invention and the expression vector described in the third aspect of the present invention. The recombinant cell is used to express or secrete the DNA polymerase mutant described in the first aspect of the present invention.
[0082] According to an embodiment of the present invention, the recombinant cell is selected from Escherichia coli, yeast or mammalian cells.
[0083] In a fifth aspect, the present invention provides a recombinant strain. According to an embodiment of the present invention, the recombinant strain expresses the DNA polymerase mutant described in the first aspect of the present invention. By culturing the recombinant strain, the DNA polymerase mutant can be rapidly obtained in large quantities.
[0084] In a sixth aspect, the present invention provides a method for obtaining a DNA polymerase mutant. According to an embodiment of the present invention, the method comprises culturing the recombinant cell described in the fourth aspect of the present invention or the recombinant strain described in the fifth aspect of the present invention under conditions suitable for protein expression, thereby obtaining the DNA polymerase mutant.
[0085] In a seventh aspect, the present invention provides a complex. According to an embodiment of the present invention, the complex comprises the DNA polymerase mutant according to the first aspect of the present invention and a small molecule compound or a macromolecule, wherein the DNA polymerase mutant and the small molecule compound or the macromolecule are coupled via a chemical bond.
[0086] According to an embodiment of the present invention, the small molecule compound or macromolecule includes a fluorescent marker, fluorescein or an antibody.
[0087] In its eighth aspect, the present invention provides a method for nucleic acid synthesis. According to an embodiment of the present invention, the method comprises: subjecting a mixture of a nucleic acid template, an amplification primer, dNTPs, and the DNA polymerase mutant described in the first aspect of the present invention to an amplification treatment under conditions suitable for nucleic acid amplification, thereby obtaining the nucleic acid. The aforementioned nucleic acid synthesis method enables efficient and rapid amplification of the nucleic acid template.
[0088] It should be noted that the DNA polymerase mutant described in the present application has polymerization activity for all dNTPs (including dNTPs with or without fluorescent labels).
[0089] In its ninth aspect, the present invention provides a method for nucleic acid sequencing. According to an embodiment of the present invention, the method comprises: subjecting a nucleic acid template to be tested to a mixture of the DNA polymerase mutant described in the first aspect of the present invention and a non-natural dNTP with a fluorescently labeled 3' O-reversible terminator, performing an amplification process and a fluorescence signal detection process under conditions suitable for nucleic acid amplification; and determining the nucleic acid sequence of the nucleic acid to be tested based on the fluorescence signal detected.
[0090] Exemplarily, the nucleic acid sequencing method includes mixing the nucleic acid template to be tested with the DNA polymerase mutant and the non-natural dNTP with a fluorescently labeled 3'O-reversible terminator, wherein the DNA polymerase mutant is responsible for matching the non-natural dNTP with the fluorescently labeled 3'O-reversible terminator with the nucleic acid template, and finally, by detecting multiple fluorescent labeling signals, the nucleic acid sequence obtained based on the obtained fluorescent labeling signals is obtained to obtain the nucleic acid sequence of the nucleic acid to be tested. The above polymerization reaction and fluorescent labeling reaction can be performed for multiple cycles according to the length of the sequencing template.
[0091] In a tenth aspect, the present invention provides a nucleic acid sequencing kit. According to embodiments of the present invention, the nucleic acid sequencing kit includes the DNA polymerase mutant described in the first aspect or the complex described in the seventh aspect. The kit of the present invention is used for efficient, accurate, and rapid nucleic acid sequencing.
[0092] In an eleventh aspect of the present invention, the present invention provides a use of the nucleic acid sequencing kit according to the ninth aspect in sequencing. According to an embodiment of the present invention, the kit can be used for sequencing, including but not limited to sequencing by synthesis (SBS).
[0093] In the twelfth aspect of the present invention, the present invention provides a use of the DNA polymerase mutant described in the first aspect, the nucleic acid molecule described in the second aspect, the expression vector described in the third aspect, the recombinant cell described in the fourth aspect, the recombinant strain described in the fifth aspect, or the complex described in the seventh aspect in the preparation of a product for catalyzing DNA amplification or nucleic acid sequencing. According to embodiments of the present invention, the DNA polymerase mutant, nucleic acid molecule, expression vector, recombinant cell, recombinant strain, or complex can be used alone or in combination to prepare a product for catalyzing DNA amplification or nucleic acid sequencing.
[0094] It should be understood that within the scope of the present invention, the above-mentioned technical features of the present invention and the technical features described in detail below (such as in the embodiments) can be combined with each other to form new or preferred technical solutions. Due to space limitations, they will not be listed here one by one. BRIEF DESCRIPTION OF THE DRAWINGS
[0095] The above and / or additional aspects and advantages of the present invention will become apparent and readily understood from the following description of the embodiments with reference to the accompanying drawings, in which:
[0096] FIG1 shows the electrophoresis diagram of the Pyrococcus abyssi exo-type DNA polymerase fusion protein described in Example 1 of the present invention. DETAILED DESCRIPTION
[0097] The embodiments of the present invention are described in detail below, and examples of the embodiments are shown in the accompanying drawings. The embodiments described below with reference to the accompanying drawings are exemplary and intended to be used to explain the present invention, but should not be understood as limiting the present invention.
[0098] Definition and Explanation
[0099] Furthermore, the terms "first" and "second" are used for descriptive purposes only and should not be construed as indicating or implying relative importance or implicitly specifying the number of the technical features being referred to. Thus, a feature defined as "first" or "second" may explicitly or implicitly include at least one such feature. In the description of the present invention, "plurality" means at least two, such as two, three, etc., unless otherwise specifically defined.
[0100] In the present application, the amino acid sequence shown in SEQ ID NO: 1 is obtained by mutating amino acid D at position 141 of the wild-type Pyrococcus abyssi DNA polymerase to A and amino acid E at position 143 to A. The wild-type Pyrococcus abyssi DNA polymerase has no exonuclease activity.
[0101] In this application, unless otherwise specified, the terms "identity" and "homology" have the same meaning.
[0102] The present invention aims to provide a B family recombinant polymerase that can improve sequencing quality. The enzyme is based on the DNA polymerase of the archaeon Pyrococcus abyssi (Erauso, et al. "Pyrococcus abyssi sp.nov., a new hyperthermophilic archaeon isolated from a deep-sea hydrothermal vent." Archives of Microbiology 160(1993):338-349). The wild-type polymerase exhibits high activity and heat resistance, but it is inefficient in incorporating non-natural dNTPs with fluorescent labels and 3'O-reversible terminators. Enzyme engineering and screening of the relevant active sites are required to improve the enzyme's incorporation efficiency for specific non-natural dNTPs for use in SBS sequencing.
[0103] DNA polymerase mutants
[0104] The present invention provides a DNA polymerase mutant. The DNA polymerase mutant provided in the embodiments of the present invention has an amino acid sequence that is at least 90% homologous to the wild-type Pyrococcus abyssi DNA polymerase exo-mutant, and has mutations at at least three of the following positions: position 409, position 410, position 411, and position 486.
[0105] The DNA polymerase mutant described in the present application has the advantages of high activity and high heat resistance, and has the ability to improve the performance of polymerizing 3'O-reversible terminator non-natural dNTPs, thereby improving sequencing speed and quality.
[0106] Nucleic acid molecules
[0107] According to some specific embodiments of the present invention, the present invention provides a nucleic acid molecule encoding the aforementioned DNA polymerase mutant.
[0108] It should be noted that, for nucleic acids mentioned in the present specification and claims, those skilled in the art will understand that they actually include any one or both of the complementary double strands. For convenience, although only one strand is provided in most cases in this specification and claims, the other complementary strand is also disclosed. In addition, the nucleic acid sequences in this application include DNA or RNA forms, and disclosure of one of them means that the other is also disclosed.
[0109] expression vector
[0110] The present invention provides an expression vector comprising the aforementioned nucleic acid molecule. The type of expression vector is not particularly limited, as long as it can replicate and express the corresponding mutant in a host cell.
[0111] recombinant cells
[0112] The present invention provides a recombinant cell carrying the aforementioned nucleic acid molecule, expression vector, or expressing a DNA polymerase mutant. The recombinant cell is obtained by transfecting or transforming the expression vector. According to some specific embodiments of the present invention, the recombinant cell can efficiently express the aforementioned DNA polymerase mutant under appropriate conditions.
[0113] Recombinant strains
[0114] The present invention provides a recombinant strain expressing the aforementioned DNA polymerase mutant. The recombinant strain can be mass-produced in a short period of time and efficiently prepare the DNA polymerase mutant.
[0115] Method for obtaining DNA polymerase mutants
[0116] The method for obtaining a DNA polymerase mutant proposed by the present invention comprises culturing the aforementioned recombinant cells under conditions suitable for protein expression to obtain the DNA polymerase mutant.
[0117] Complex
[0118] The present invention provides a complex comprising the aforementioned DNA polymerase mutant and a small molecule compound or a macromolecule, wherein the DNA polymerase mutant and the small molecule compound or macromolecule are chemically coupled. In the field of gene sequencing, the nucleic acid sequence to be detected is determined by detecting the small molecule compound (fluorescent marker) or macromolecule (antibody, fluorescein) in the complex.
[0119] The present invention is described below with reference to specific examples. It should be noted that these examples are merely illustrative and do not limit the present invention in any way.
[0120] Example 1
[0121] According to an embodiment of the present invention, DNA polymerase and its mutants were prepared and crude enzyme activity screened based on Pyrococcus abyssi exo-type (deep-sea fireball bacteria exo-mutant). The specific steps are as follows:
[0122] 1.1 Construction and transformation of recombinant expression vector
[0123] Sangon Biotech (Shanghai) Co., Ltd. synthesized the pD441-WT vector plasmid containing the Pyrococcus abyssi exo-type DNA polymerase gene (SEQ ID NO: 1) fused with a C-terminal 6x His tag and site-directed mutagenesis primers at sites 409, 410, 411, and 485.
[0124] The primers were designed as follows: 5'-reverse complementary region (15-21 bp)-non-complementary region (at least 15 bp). Phanta Max Super-Fidelity DNA Polymerase was used to amplify the target plasmid.
[0125] The 409, 410, 411, and 485 positions were mutated to the following amino acids:
[0126] L409 mutated to A, F, H, L, Q, S, V, Y;
[0127] Y410 mutated to A, G;
[0128] P411 mutated to A, C, E, F, H, I, K, L, M, N, P, Q, R, S, T, V, W, Y;
[0129] A485 mutated to F, I, L, K, M, W;
[0130] A mutant site combination known to exhibit superior polymerization activity for 3'O-reversible terminators of non-natural dNTPs in other B-family polymerases (9°N, Pfu, Vent, etc.) is L409A-Y410A-P411I-A486L in 9°N polymerase (patents EP1664287B1 and US8460910B2). This mutant combination will serve as a control mutation site combination (SEQ ID NO: 2) in Pyrococcus abyssi polymerase screening experiments.
[0131] Part of the mutation combinations of the four sites in the enzyme mutants is shown in Figure 1, where the control mutant Mut1 combination is L409A-Y410A-P411I-A486L.
[0132] Table 1:
[0133] Since the amplified product contains the original template plasmid, in order to prevent the formation of false positive transformants after transformation, Dpn I digestion must be performed before recombination circularization to remove the methylated template plasmid.
[0134] Transduce the recombinant polymerase mutant expression vector into competent E. coli BL21 cells and screen for positive colonies using resistance plates (containing 50 μg / ml kanamycin). After overnight incubation, single colonies from the experimental group were selected and incubated overnight in 5 ml of LB medium (containing 50 μg / ml kanamycin) at 37°C, 200 rpm / min. The next day, dilute the cells 1:100 and transfer them to a 96-well plate containing 150 μl of fresh LB medium (containing 50 μg / ml kanamycin) and shake-culture at 37°C, 220 rpm, until an OD600 of 0.6 was reached.
[0135] 1.2 Recombinant protein expression and bacterial lysis
[0136] In the 96-well plate prepared in step 1.1, add IPTG (isopropylthiogalactoside) to a final concentration of 0.5 mM and incubate at 25°C, 220 rpm / min, for 12-16 hours to induce expression. Then, add 1 μL of 100 mM PMSF (a protease inhibitor) and 5 μL of 10 mg / ml lysozyme. Gently pipette and mix thoroughly. Incubate at 37°C for 10 minutes to obtain a crude enzyme solution.
[0137] 1.3 Fret recombinant protein and non-natural dNTP incorporation efficiency test
[0138] Add AF532 fluorescent dye-labeled 3'O-blocked modified dATP (MGI patent US10988501B2) and Cy5 fluorescent dye-labeled DNA chain (Sangon Biotech (Shanghai) Co., Ltd.) to the crude enzyme solution obtained in step 1.2. The sequence information is:
[0139] F: Cy5-CGTGTATGCGTAATAGGATCCCGACTCACTATGGACG;
[0140] R: Cy5-CGTGTATCGTCCATAGTGAGTCGGGATCCTATTACGC.
[0141] To simulate the incorporation of modified nucleotides during high-throughput sequencing, a microplate reader was used to detect the relative reaction rates of polymerase mutants and calculate crude enzyme activity. The specific experimental method is as follows:
[0142] Reaction buffer: 20 mM Tris-HCl, 10 mM (NH4)2SO4, 10 mM KCl, 2 mM MgSO4, pH 8.5 at 25°C;
[0143] The reaction system is as follows: 1 μg of different polymerase proteins obtained in step 1.2 are mixed with a reaction solution containing 2 μM modified dATP and 1 μM DNA-Cy5;
[0144] Reaction solution formula: 20mM Tris-HCl, 10mM (NH4)2SO4, 10mM KCl, 2mM MgSO4, 2uM 3' blocking modified dATP and 1μM DNA-Cy5, the balance is water, pH 8.5;
[0145] Reaction temperature: 60°C;
[0146] Reaction time: 1h.
[0147] After the reaction was complete, the data table and enzyme activity curve were exported, and the relative activity (Relative Vmax / Km) of the crude enzyme was calculated compared to the control enzyme mutant P1. Some of the results are shown in Table 1. While the wild-type P0 (WT-Exo-) Pyrococcus abyssi exo-type DNA polymerase was unable to incorporate 3'-O-blocked modified dATP labeled with the AF532 fluorescent dye, some mutant proteins were able to incorporate it, generating fluorescent signals. The experimental results show that different mutants exhibited varying polymerization activities toward modified 3'-blocked dNTPs, indicating effective mutations and site combinations at different sites. Mutation site combinations listed in the table with higher Ralative Vmax / Km values than the control are considered mutants that efficiently incorporate 3'-blocked dNTPs. This suggests that these mutants have great potential for application in high-throughput sequencing.
[0148] Example 2
[0149] According to an embodiment of the present invention, the expression and purification of a DNA polymerase mutant fusion protein was performed based on the Pyrococcus abyssi exo-type (deep-sea fireball bacteria exo-mutant). The specific steps are as follows:
[0150] 1) Pick a single BL21 / pD441 mutant colony and culture it in 50 ml of LB liquid culture medium (containing 50 μg / ml kanamycin) at 37°C, 220 rpm / min, overnight. The next day, dilute the culture 1:100 and transfer it to 1000 ml of LB liquid culture medium (containing 50 μg / ml kanamycin). Cultivate the culture at 37°C, 220 rpm / min, and shake until the OD600 reaches 0.5-0.8. Add IPTG to a final concentration of 0.5 mM and induce the culture overnight at 25°C. Collect the induced BL21 / pD441 culture. Simultaneously, collect the uninduced BL21 / pD441 culture without IPTG as a blank control.
[0151] 2) The BL21 / pD441 bacterial suspension induced in step 1) was centrifuged at 8000 rpm / min for 10 min, the supernatant was discarded, the precipitated cells were collected, and the cells were resuspended in buffer 1 (50 mM KPO4, 500 mM NaCl, 10 mM imidazole, 5% Glycerol, pH 7.0), and PMSF (final concentration 0.5 mM) and Triton X-ray distillation were added. X-100 (final concentration 0.5%) and Lysozyme (lysozyme, final concentration 0.25%) were added, followed by incubation at room temperature for 30 min, centrifugation at 12,000 rpm / min and 4°C for 30 min, ice bath, and ultrasonic cell disruption; centrifugation at 12,000 rpm / min for 30 min, and the supernatant obtained by centrifugation was placed in a 75°C water bath for 20 min, with regular mixing during the period to ensure uniform heating; centrifugation at 12,000 rpm / min and 4°C for 30 min, and the supernatant was filtered through a 0.22 μm filter membrane to obtain a crude fusion protein extract.
[0152] 3) The crude fusion protein extract obtained in step 2) was loaded onto a Ni column affinity chromatography (affinity chromatography prepacked column HisTrap FF, 5 ml, 17-5255-01, GE healthcare) at an appropriate flow rate. After loading, the column was equilibrated with buffer 1 for 5 CV (column volume); eluted with 3% buffer 2 (50 mM KPO4, 1 M NaCl, 5% Glycerol, pH 7.0) for 5 CV; and eluted with 50% buffer 2 for 5 CV. The Ni column affinity chromatography eluate corresponding to the peak value greater than or equal to 100 mAU was collected.
[0153] 4) The eluate corresponding to the peak with a concentration of 100 mAU or greater was loaded at a specific flow rate for ion exchange chromatography (prepacked ion exchange column HiTrap Q HP, 5 ml, 17-1154-01, GE healthcare). After loading, the column was equilibrated with buffer 2 for 5 CV and linearly eluted from 0% buffer 2 to 60% buffer 2. The eluate corresponding to the peak with a concentration of 100 mAU or greater was collected.
[0154] 5) The ion exchange chromatography eluate corresponding to the peak of 100 mAU or more was subjected to gel chromatography (gel chromatography prepacked column HiPrep Sephacryl S-100HR, 26 mm, 17-1194-01, GE healthcare). The column was first washed with 20% ethanol for 3 CV, then washed with water for 3 CV, equilibrated with 100% buffer 3 (20 mM Tris, 200 mM KCl, 0.2 mM EDTA, 10% Glycerol, pH 7.4) for 3 CV, and then loaded. The column was then eluted with buffer 3 for 1.5 CV, and the eluate was collected to obtain the purified wild-type DNA polymerase fusion protein.
[0155] 6) The Pyrococcus abyssi exo-type DNA polymerase fusion protein was subjected to SDS-PAGE (5% stacking gel, 12% resolving gel). The results are shown in Figure 1 , where lane 1 represents protein marker (PageRuler Prestained Protein Ladder, 26616, Thermo Scientific), lane 2 represents 1 μl of crude fusion protein supernatant, and lane 3 represents 1 μl of the Pyrococcus abyssi exo-type DNA polymerase mutant fusion protein purified by 1 mg / ml Ni column affinity chromatography. It can be seen that the protein size in lanes 2 and 3 is approximately 90 kDa, which is consistent with the molecular weight reported in the literature (Dietrich, J., Schmitt, P., Zieger, M., Preve, B., Rolland, JL, Chaabihi, H., & Gueguen, Y. (2002). PCR performance of the highly thermostable proof-reading B-type DNA polymerase from Pyrococcus abyssi. FEMS microbiology letters, 217(1), 89-94.). The protein purity was analyzed using Quantity One software on the protein gel after electrophoresis. The purity of the purified DNA polymerase mutant fusion protein can reach 85% or above. The target protein of approximately 90 kDa was not obtained in the uninduced BL21 / pD441 bacterial solution.
[0156] Example 3
[0157] According to an embodiment of the present invention, the actual sequencing performance test of the purified enzyme of the DNA polymerase mutant in the sequencer was performed based on the Pyrococcus abyssi exo-type (deep-sea fireball exo-mutant). Among them, the purified enzyme of the dominant mutant was sequenced on the MGISEQ-2000 sequencer of BGI, and the sequencing results were analyzed. The specific experimental steps are as follows:
[0158] Sequencing library: Ecoli.fa library (Part No. 1000005038, MGI Tech co., Ltd);
[0159] Sequencing conditions: polymerization time 90 seconds, excision time 60 seconds.
[0160] Using the same sequencing library, Ecoli.fa, and sequencing conditions, we selected a control P1 mutant and five mutants that exhibited varying performance in the enzyme activity test for on-line testing. These mutants were sequenced for 100 cycles (SE100) on the MGISEQ-2000 sequencer. The test results, shown in Table 2, demonstrate that the purified enzyme from the dominant mutant performed better in actual sequencing.
[0161] Table 2:
[0162] In the description of this specification, the reference terms "one embodiment", "some embodiments", "example", "specific example", or "some examples" mean that the specific features, structures, materials or characteristics described in conjunction with the embodiment or example are included in at least one embodiment or example of the present invention. In this specification, the schematic representations of the above terms do not necessarily refer to the same embodiment or example. Moreover, the specific features, structures, materials or characteristics described can be combined in any one or more embodiments or examples in a suitable manner. In addition, those skilled in the art can combine and combine different embodiments or examples described in this specification and features of different embodiments or examples without contradiction.
[0163] Although the embodiments of the present invention have been shown and described above, it will be understood that the above embodiments are illustrative and are not to be construed as limitations on the present invention. A person skilled in the art may change, modify, replace and modify the above embodiments within the scope of the present invention.
Claims
1. A DNA polymerase mutant, characterized in that: Compared to a Pyrococcus abyssi DNA polymerase exo-mutant, the exo-mutant has at least three amino acid mutations in the following four positions or functionally equivalent positions: No. 409, No. 410, No. 411, No. 486; The Pyrococcus abyssi DNA polymerase exo-mutant has an amino acid sequence as shown in SEQ ID NO:
1.
2. The DNA polymerase mutant according to claim 1, characterized in that The DNA polymerase mutant is at least 90% identical to the Pyrococcus abyssi DNA polymerase exo-mutant.
3. The DNA polymerase mutant according to claim 1, characterized in that The mutant has the following mutations: (1) The amino acid L at position 409 is mutated to A, V, Y, H, F or Q; (2) amino acid Y at position 410 mutated to A or G; (3) the amino acid P at position 411 does not mutate or mutates to V, G, C, or S; (4) The amino acid A at position 486 is mutated to I, K, L, M, W or F.
4. The DNA polymerase mutant according to claim 3, characterized in that The mutant has any one of the following combined mutations (1)-(2): (1) the amino acid Y at position 410 is mutated to A, the amino acid L at position 409 is mutated to A, V, Y, H, F, or Q, the amino acid P at position 411 is mutated to V, G, C, S, or no mutation, and the amino acid A at position 486 is mutated to I, K, L, M, W, or F; or (2) The amino acid Y at position 410 mutates to G, the amino acid L at position 409 mutates to A, V, Y, H, F, or Q, the amino acid P at position 411 mutates to V, G, C, S, or no mutation, and the amino acid A at position 486 mutates to I, K, L, M, W, or F.
5. The DNA polymerase mutant according to claim 3, characterized in that The mutant has any one of the following combined mutations (1)-(7): (1) the amino acid Y at position 410 is mutated to A, the amino acid L at position 409 is mutated to A, the amino acid P at position 411 is mutated to G, C, S or no mutation, and the amino acid A at position 486 is mutated to I, K, L, M, W or F; or (2) the amino acid Y at position 410 is mutated to A, the amino acid L at position 409 is mutated to V, the amino acid P at position 411 is mutated to V, G, C or no mutation, and the amino acid A at position 486 is mutated to I, L, W or F; or (3) the amino acid Y at position 410 mutates to A, the amino acid L at position 409 mutates to Y, the amino acid P at position 411 mutates to V or G or does not mutate, and the amino acid A at position 486 mutates to L; or (4) the amino acid Y at position 410 is mutated to A, the amino acid L at position 409 is mutated to H, the amino acid P at position 411 is mutated to V or G or is not mutated, and the amino acid A at position 486 is mutated to L; or (5) The 410th amino acid Y mutated to A, the 409th amino acid L mutated to F, and the 411th amino acid P mutated to V or G or no mutation, and the 486th amino acid A mutates to L; or (6) the amino acid Y at position 410 is mutated to A, the amino acid L at position 409 is mutated to Q, the amino acid P at position 411 is mutated to G or not mutated, and the amino acid A at position 486 is mutated to L; or (7) The amino acid Y at position 410 mutates to G, the amino acid L at position 409 mutates to V, the amino acid P at position 411 does not mutate, and the amino acid A at position 486 mutates to I, K, M, or F.
6. The DNA polymerase mutant according to claim 4, characterized in that The mutant has any one of the combined mutations (1)-(36): (1) L at position 409 is mutated to A, Y at position 410 is mutated to A, P at position 411 is not mutated, and A at position 486 is mutated to I; or (2) L at position 409 is mutated to V, Y at position 410 is mutated to A, P at position 411 is not mutated, and A at position 486 is mutated to L; or (3) L at position 409 is mutated to A, Y at position 410 is mutated to A, P at position 411 is not mutated, and A at position 486 is mutated to W; or (4) L at position 409 is mutated to V, Y at position 410 is mutated to G, P at position 411 is not mutated, and A at position 486 is mutated to K; or (5) L at position 409 is mutated to V, Y at position 410 is mutated to G, P at position 411 is not mutated, and A at position 486 is mutated to I; or (6) L at position 409 is mutated to A, Y at position 410 is mutated to A, P at position 411 is not mutated, and A at position 486 is mutated to M; or (7) L at position 409 is mutated to V, Y at position 410 is mutated to G, P at position 411 is not mutated, and A at position 486 is mutated to F; or (8) L at position 409 mutates to V, Y at position 410 mutates to A, P at position 411 mutates to V, and A at position 486 mutates to L; or (9) L at position 409 is mutated to A, Y at position 410 is mutated to A, P at position 411 is not mutated, and A at position 486 is mutated to F; or (10) L at position 409 mutates to A, Y at position 410 mutates to A, P at position 411 mutates to G, and A at position 486 mutates to I; or (11) L at position 409 mutates to A, Y at position 410 mutates to A, P at position 411 mutates to C, and A at position 486 mutates to I; or (12) L at position 409 mutated to Y, Y at position 410 mutated to A, P at position 411 did not mutate, and A at position 486 mutated to becomes L; or (13) L at position 409 mutates to A, Y at position 410 mutates to A, P at position 411 mutates to S, and A at position 486 mutates to K; or (14) L at position 409 mutates to Y, Y at position 410 mutates to A, P at position 411 mutates to G, and A at position 486 mutates to L; or (15) L at position 409 mutates to Y, Y at position 410 mutates to A, P at position 411 mutates to V, and A at position 486 mutates to L; or (16) L at position 409 is mutated to H, Y at position 410 is mutated to A, P at position 411 is not mutated, and A at position 486 is mutated to L; or (17) L at position 409 is mutated to F, Y at position 410 is mutated to A, P at position 411 is not mutated, and A at position 486 is mutated to L; or (18) L at position 409 is mutated to A, Y at position 410 is mutated to A, P at position 411 is not mutated, and A at position 486 is mutated to L; or (19) L at position 409 mutates to A, Y at position 410 mutates to A, P at position 411 mutates to C, and A at position 486 mutates to M; or (20) L at position 409 is mutated to V, Y at position 410 is mutated to G, P at position 411 is not mutated, and A at position 486 is mutated to M; or (21) L at position 409 mutates to A, Y at position 410 mutates to A, P at position 411 mutates to G, and A at position 486 mutates to W; or (22) L at position 409 mutates to A, Y at position 410 mutates to A, P at position 411 mutates to G, and A at position 486 mutates to M; or (23) L at position 409 is mutated to V, Y at position 410 is mutated to A, P at position 411 is not mutated, and A at position 486 is mutated to W; or (24) L at position 409 mutates to V, Y at position 410 mutates to A, P at position 411 mutates to C, and A at position 486 mutates to L; or (25) L at position 409 mutates to Q, Y at position 410 mutates to A, P at position 411 mutates to G, and A at position 486 mutates to L; or (26) L at position 409 mutates to H, Y at position 410 mutates to A, P at position 411 mutates to G, and A at position 486 mutates to L; or (27) L at position 409 mutated to A, Y at position 410 mutated to A, P at position 411 mutated to S, and A at position 486 mutated to mutated to F; or (28) L at position 409 is mutated to V, Y at position 410 is mutated to A, P at position 411 is not mutated, and A at position 486 is mutated to I; or (29) L at position 409 mutates to H, Y at position 410 mutates to A, P at position 411 mutates to V, and A at position 486 mutates to L; or (30) L at position 409 mutates to A, Y at position 410 mutates to A, P at position 411 mutates to S, and A at position 486 mutates to I; or (31) L at position 409 mutates to A, Y at position 410 mutates to A, P at position 411 mutates to S, and A at position 486 mutates to M; or (32) L at position 409 mutates to F, Y at position 410 mutates to A, P at position 411 mutates to G, and A at position 486 mutates to L; or (33) L at position 409 mutates to V, Y at position 410 mutates to A, P at position 411 mutates to G, and A at position 486 mutates to L; or (34) L at position 409 is mutated to V, Y at position 410 is mutated to A, P at position 411 is not mutated, and A at position 486 is mutated to F; or (35) L at position 409 mutates to A, Y at position 410 mutates to A, P at position 411 mutates to G, and A at position 486 mutates to F; or (36) L at position 409 mutated to F, Y at position 410 mutated to A, P at position 411 mutated to V, and A at position 486 mutated to L.
7. The DNA polymerase mutant according to claim 1, characterized in that The mutant has the following mutations: (1) L at position 409 is mutated to V, Y at position 410 is mutated to G, P at position 411 is not mutated, and A at position 486 is mutated to I; or (2) L at position 409 is mutated to A, Y at position 410 is mutated to A, P at position 411 is not mutated, and A at position 486 is mutated to I; or (3) L at position 409 mutates to A, Y at position 410 mutates to A, P at position 411 does not mutate, and A at position 486 mutates to M; or (4) L at position 409 is mutated to A, Y at position 410 is mutated to A, P at position 411 is not mutated, and A at position 486 is mutated to L; or (5) L at position 409 is mutated to V, Y at position 410 is mutated to A, P at position 411 is not mutated, and A at position 486 is mutated to I; or (6) L at position 409 mutated to A, Y at position 410 mutated to A, P at position 411 mutated to C, and A at position 486 mutated to F.
8. A nucleic acid molecule, characterized in that The nucleic acid molecule encodes the DNA polymerase mutant according to any one of claims 1 to 7.
9. An expression vector, characterized in that Comprising the nucleic acid molecule of claim 9.
10. The expression vector according to claim 9, characterized in that The expression vector is a non-pathogenic viral vector; The non-pathogenic viral vector includes an adenoviral vector or a retroviral vector.
11. A recombinant cell, characterized in that Carrying the nucleic acid molecule according to claim 9 or the expression vector according to claim 10.
12. The recombinant cell according to claim 11, characterized in that The recombinant cell is selected from Escherichia coli, yeast or mammalian cells.
13. A recombinant strain, characterized in that: The recombinant strain expresses the DNA polymerase mutant according to any one of claims 1 to 7.
14. A method for obtaining a DNA polymerase mutant, characterized in that: include: The recombinant cell according to any one of claims 11 to 12 or the recombinant strain according to claim 13 is cultured under conditions suitable for protein expression to obtain the DNA polymerase mutant.
15. A composite, characterized in that The invention comprises the DNA polymerase mutant according to any one of claims 1 to 7 and a small molecule compound or a macromolecule, wherein the mutant and the small molecule compound or the macromolecule are coupled via a chemical bond.
16. The composite according to claim 15, characterized in that The small molecule compound or macromolecule includes a fluorescent marker, fluorescein or an antibody.
17. A method for synthesizing nucleic acid, characterized in that: include: The mixed product of nucleic acid template, amplification primer, dNTP and the DNA polymerase mutant according to any one of claims 1 to 7 is subjected to amplification treatment under conditions suitable for nucleic acid amplification to obtain the nucleic acid.
18. A method for nucleic acid sequencing, characterized in that: include: Amplify the nucleic acid to be tested and perform fluorescence signal detection on the mixed product of the DNA polymerase mutant according to any one of claims 1 to 7 and the non-natural dNTP with a fluorescently labeled 3'O-reversible terminator under conditions suitable for nucleic acid amplification; as well as Based on the fluorescent signal obtained by detection, the nucleic acid sequence of the nucleic acid to be detected is determined.
19. A nucleic acid sequencing kit, characterized in that: It comprises the DNA polymerase mutant according to any one of claims 1 to 7 or the complex according to claim 15 or 16.
20. Use of the nucleic acid sequencing kit according to claim 19 in sequencing.
21. Use of the DNA polymerase mutant according to any one of claims 1 to 7, the nucleic acid molecule according to claim 8, the expression vector according to any one of claims 9 to 10, the recombinant cell according to any one of claims 11 to 12, the recombinant strain according to claim 13 or the complex according to any one of claims 15 to 16 in the preparation of products related to catalysis of DNA amplification or nucleic acid sequencing.
Citation Information
Patent Citations
Modified b type DNA polymerases for improved incorporation of nucleotide analogues
EP1664287B1
Reversibly blocked nucleoside analogues and their use
US10988501B2
Modified polymerases for improved incorporation of nucleotide analogues
US8460910B2
Polymerases, compositions, and methods of use
CN112673098A
Modified archaeal family B polymerases
US11136565B2
